Oral Paricalcitol: A Viewpoint by James B. Wetmore and L. Darryl Quarles

By Wetmore James B.   Quarles L. Darryl  

Treatments in Endocrinology, Vol. 5, Iss. 5, 2006-01 ,pp. : 326-327

Adis International

Access to resources Recommend Favorite

Treatment with oral paricalcitol in daily clinical practice for patients with chronic kidney disease stage 3-4: a preliminary study

By Hadjiyannakos Dimitrios   Filiopoulos Vassilis   Trompouki Sofia   Sonikian Makroui   Karatzas Ioannis   Panagiotopoulos Konstantinos   Vlassopoulos Dimosthenis  

Clinical Kidney Journal, Vol. 6, Iss. 2, 2013-04 ,pp. : 164-168

Oxford University Press

Access to resources Recommend Favorite

Spotlight on Paricalcitol in Secondary Hyperparathyroidism

By Robinson Dean M.   Scott Lesley J.  

Treatments in Endocrinology, Vol. 4, Iss. 3, 2005-01 ,pp. : 185-186

Adis International

Access to resources Recommend Favorite

Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model

By ARI E   KEDRAH A E   ALAHDAB Y   BULUT G   EREN Z   BAYTEKIN O   ODABASI D  

British Journal of Radiology, Vol. 85, Iss. 1016, 2012-08 ,pp. : 1038-1043

British Institute of Radiology

Access to resources Recommend Favorite

Pathogenesis and Treatment of Secondary Hyperparathyroidism in Dialysis Patients: The Role of Paricalcitol

By  

Current Vascular Pharmacology, Vol. 6, Iss. 2, 2008-04 ,pp. : 148-153

Bentham Science Publishers

Access to resources Recommend Favorite